BIOMARIN PHARMACEUTICAL INC Payments to Acquire Available-for-sale Securities
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Payments to Acquire Available-for-sale Securities of $345.46 million for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-03.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecurities · last filed 2018-08-03
- BIOMARIN PHARMACEUTICAL INC payments to acquire available-for-sale securities for the quarter ending 2018-06-30 was $199.53M, a 160.48% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire available-for-sale securities for the quarter ending 2018-03-31 was $145.93M, a 168.32% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire available-for-sale securities for the quarter ending 2017-09-30 was $478.81M, a 53.72% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC payments to acquire available-for-sale securities for the quarter ending 2017-06-30 was $76.60M.
| Period end | Payments to Acquire Available-for-sale Securities 3 month | Payments to Acquire Available-for-sale Securities 6 month | Payments to Acquire Available-for-sale Securities 9 month |
|---|---|---|---|
| 2018-06-30 | $199.53M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $345.46M 10-Q · filed 2018-08-03 | |
| 2018-03-31 | $145.93M 10-Q · filed 2018-04-27 | ||
| 2017-09-30 | $478.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $555.41M derived: sum of 2 quarters · filed 2018-08-03 | $609.79M 10-Q · filed 2017-10-31 |
| 2017-06-30 | $76.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-03 | $130.99M 10-Q · filed 2018-08-03 | |
| 2017-03-31 | $54.39M 10-Q · filed 2018-04-27 | ||
| 2016-09-30 | $311.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-10-31 | $311.48M derived: sum of 2 quarters · filed 2017-10-31 | $370.39M 10-Q · filed 2017-10-31 |
| 2016-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | $58.91M 10-Q · filed 2017-08-02 | |
| 2016-03-31 | $58.91M 10-Q · filed 2017-05-04 | ||
| 2015-09-30 | $842.87M 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |